Identifying the molecular basis of Jinhong tablets against chronic superficial gastritis via chemical profile identification and symptom-guided network pharmacology analysis

Chronic superficial gastritis(CSG)is a common disease of the digestive system that possesses a serious pathogenesis.Jinhong tablet(JHT),a traditional Chinese medicine(TCM)prescription,exerts therapeutic effects against CSG.However,the molecular basis of its therapeutic effect has not been clarified.Herein,we employed ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry(UPLC-Q/TOF-MS)based chemical profile identification to determine the chemical components in JHT.Further,we applied network pharmacology to illustrate its molecular mechanisms.A total of 96 chemical constituents were identified in JHT,31 of which were confirmed using reference standards.Based on the bioinformatics analysis using the symptom-guided pharmacological networks of“chi,”“blood,”“pain,”and“inflammation,”and target screening through the interaction probabilities between compounds and targets,matrix metalloproteinase 2(MMP2),dopamine d2 receptor(DRD2),and Aldo-keto reductase family 1 member B1(AKR1B1)were identified as key targets in the therapeutic effect exhibited by JHT against CSG.Moreover,according to the inhibitory activities presented in the literature and binding mode analysis,the structural types of alkaloids,flavonoids,organic acids,including chlorogenic acid(10),caffeic acid(13),(-)-corydalmine(33),(-)-isocorypalmine(36),isochlorogenic acid C(38),isochlorogenic acid A(41),quercetin-3-O-a-L-rhamnoside(42),isochlorogenic acid B(47),quercetin(63),and kaempferol(70)tended to show remarkable activities against CSG.Owing to the above findings,we systematically identified the chemical components of JHT and revealed its molecular mechanisms based on the symptoms associated with CSG.

Evaluation of the Gastric Microbiome in Patients with Chronic Superficial Gastritis and Intestinal Metaplasia

Objective To evaluate the gastric microbiome in patients with chronic superficial gastritis(CSG)and intestinal metaplasia(IM)and investigate the influence of Helicobacter pylori(H.pylori)on the gastric microbiome.Methods Gastric mucosa tissue samples were collected from 54 patients with CSG and IM,and the patients were classified into the following four groups based on the state of H.pylori infection and histology:H.pylori-negative CSG(n=24),H.pylori-positive CSG(n=14),H.pylori-negative IM(n=11),and H.pylori-positive IM(n=5).The gastric microbiome was analyzed by 16S rRNA gene sequencing.Results H.pylori strongly influenced the bacterial abundance and diversity regardless of CSG and IM.In H.pylori-positive subjects,the bacterial abundance and diversity were significantly lower than in H.pylori-negative subjects.The H.pylori-negative groups had similar bacterial composition and bacterial abundance.The H.pylori-positive groups also had similar bacterial composition but different bacterial relative abundance.The relative abundance of Neisseria,Streptococcus,Rothia,and Veillonella were richer in the I-HP group than in G-HP group,especially Neisseria(t=175.1,P<0.001).Conclusions The gastric microbial abundance and diversity are lower in H.pylori-infected patients regardless of CSG and IM.Compared to H.pylori-positive CSG group and H.pylori-positive IM,the relative abundance of Neisseria,Streptococcus,Rothia,and Veillonella is higher in H.pylori-positive patients with IM than in H.pylori-positive patients with CSG,especially Neisseria.

Serum protein profiles suggest a possible link between qi deficiency constitution and Pi-qi-deficiency syndrome of chronic superficial gastritis

Objective:To identify potential serum protein candidates involved in linking the traditional Chinese medicine(TCM)-defined qi deficiency constitution(QDC)to Pi-qi-deficiency syndrome(PQDS)of chronic superficial gastritis(CSG).Methods:Using participants with the TCM-defined balanced constitution as a control population,labelfree quantitative proteomics was adopted to identify differentially expressed proteins(DEPs)in serum samples from two case populations:case population 1(participants with QDC)and case population 2(patients with PQDS of CSG).The DEPs discovered in both case populations were analyzed to identify common DEPs as potential candidates for proteins involved in the link between QDC and PQDS.Based on Kyoto Encyclopedia of Genes and Genomes pathway(KEGG)and Gene Ontology(GO)enrichment analysis and analysis of proteineprotein interaction networks,we evaluated the possible functions of these potential serum candidates.Results:We discovered 24 and 28 proteins that were differentially expressed in case populations 1 and 2,respectively,compared with the control population.Hierarchical clustering analysis showed that the expression profile of DEPs of individuals from the same population clustered well,while those from different populations were segregated.Furthermore,GO analysis revealed the 10 DEPs that were common to both case populations to be mainly associated with negative regulation of cellular metabolic and immune system processes while KEGG analysis indicated these proteins to be associated with complement and coagulation cascades and peroxisome proliferator-activated receptor signaling.Notably,serum levels of C4b-binding protein beta chain,glycosylphosphatidylinositol-specific phospholipase D1 and MS-F1 light chain variable region proteins were notably higher in the two case populations compared with the control,particularly in the case of CSG with PQDS.Conclusion:The results presented here provide new insights into the molecular mechanisms underlying development of PQDS of CSG from QDC,and suggest candidate serum biomarkers for future application in integrative medicine.

Systematic evaluation and Meta-analysis of the efficacy of Xiaochaihu Decoction in the treatment of chronic superficial gastritis

Objective:To compare the effectiveness of Xiaochaihu Decoction(XCHD)or the modified XCHD combined with western medicine in the treatment of superficial gastritis.Methods:We collected the studies about XCHD or the modified XCHD combined with western medicine for superficial gastritis in China Biology Medicine(CBM)Database(2010-2018),China National Knowledge Infrastructure(CNKI)Database(2010-2018),VIP Database(2010-2018),Wanfang Database(2010-2018)and the Back Issues Database of Hebei University.The randomized controlled trials(RCTs)were included in this study.The literatures were independently extracted by two researchers and the Cochrane Review Handbook(version 5.1.0)was applied to assess the quality of included trials.Statistical analysis was performed with RevMan(version 5.3).Results:A total of 8 RCTs,including 732 cases,were included finally.Meta-analysis results showed that compared with the western medicine treatment group,XCHD or the modified XCHD combined with western medicine could improve the total effective rate[OR=4.67,95%CI(2.90,7.55),P<0.00001],physiological function[MD=10,95%CI(8.78,11.23),P<0.00001],role physical[MD=13.85,95%CI(11.19,16.51),P<0.00001],physical pain[MD=11.64,95%CI(9.05,14.23),P<0.00001],general health[MD=11.20,95%CI(9.52,12.88),P<0.00001],vitality[MD=13.46,95%CI(12.30,14.62),P<0.00001],social function[MD=19.20,95%CI(17.32,21.09),P<0.00001],affection function[MD=30.3,95%CI(28.99,31.62),P<0.00001],mental health[MD=9.80,95%CI(8.44,11.16),P<0.00001].Conclusion:XCHD or the modified XCHD combined with western medicine in the treatment of superficial gastritis has good performance in clinical efficacy and the improvement of quality of life.However,with several methodology problems existing in the included RCTs,the effectiveness of XCHD or the modified XCHD is still need more high-quality randomized,double-blind,placebo-controlled trials to further confirmed.

Screening for blood leukocyte microRNA biomarkers responsible for association between qi deficiency constitution and Pi-qi-deficiency syndrome of chronic superficial gastritis

Objective:To screen for blood leukocyte microRNA(miRNA)biomarkers responsible for the association between the traditional Chinese medicine(TCM)qi deficiency constitution(QDC)and the Pi-qi-deficiency syndrome(PQDS)of chronic superficial gastritis(CSG).Methods:Peripheral blood leukocytes were separated from people of two TCM constitutions(balance and qi deficiency)and from CSG patients with PQDS.Total RNA was isolated from the leukocytes and subjected to subsequent high-throughput miRNA sequencing to identify the miRNAs that are specifically and highly expressed in persons of QDC and CSG patients with PQDS.In addition,the target genes of the associated miRNAs were predicted.Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway-based enrichment analyses of these target genes were performed to further evaluate the associated miRNA candidates as potential biomarkers responsible for the association between QDC and PQDS of CSG.Results:Compared with the control group with a balance constitution(P<.05,fold change>1.5 or<0.5),31 and 38 differentially expressed miRNAs were found in persons of QDC and CSG patients with PQDS,respectively.In particular,hsa-miR-145-5p and hsa-miR-146a-3p were highly expressed in both the persons of QDC and CSG patients with PQDS.GO analysis of the target genes of the two common miRNAs showed that they were mainly associated with functions related to synthesis and metabolism,such as cellular nitrogen compound metabolic processes,biosynthetic processes,cellular protein modification processes,and cellular component assembly.KEGG analysis identified the common pathways enriched among the target genes,including the Hippo signaling pathway and the transcriptional misregulation pathway.The common target genes of the two miRNAs seemed to be associated with the spliceosome pathway and the RNA degradation pathway.Conclusion:Hsa-miR-145-5p and hsa-miR-146a-3p may serve as candidate biomarkers responsible for the association between QDC and PQDS of CSG.

A Long-Term Follow-up Study of Chronic Gastritis with Fibergastroscope

A more than 5 year follow up study about 48 cases of chronic atrophic gastritis(CAG) and 100 cases of chronic superficial gastritis (CSG) is reported in CAG, it is found that 35.5% of the patients were improved, 41.6% stabilized, 12.5% deteriorated, 6.2% recovered, and 4.2% cancerated. In CSG, it is found that 40% of the patients were improved, 48% stabilized, 6% deteriorated, 5% recovered and 1% cancerated. It is concluded that CAG group has a higher rate of cancerization than that of CSG group.

双歧杆菌三联活菌胶囊联合四联疗法治疗Hp阳性CSG疗效

目的探讨双歧杆菌三联活菌胶囊联合四联疗法治疗幽门螺杆菌(Hp)阳性慢性浅表性胃炎(CSG)的疗效,以及对炎症反应、氧化应激的影响。方法选择2020年7月至2021年7月Hp+CSG患者60例,随机分为A组与B组,各30例。两组患者均接受四联疗法治疗,B组联合双歧杆菌三联活菌胶囊治疗,治疗2个月后,比较两组临床疗效及炎症细胞因子、氧化应激指标。结果B组总有效率(96.67%)比A组(76.67%)高(P=0.023);Hp根除率(100.00%)较A组(83.33%)高(P=0.020);血清炎症指标IL-6、IL-8及CRP分别为(30.84±1.97)ng/L、(19.86±1.54)ng/L、(6.47±1.24)mg/L均比A组(46.38±3.91)ng/L、(22.98±1.22)ng/L、(9.82±2.47)mg/L低(P<0.001);氧化应激指标MDA水平(6.06±0.74)μmol/L比A组(7.19±0.81)μmol/L低(P=0.001);SOD及GSH-Px水平(1.76±0.26)U/mL与(23.01±1.13)U/mL均比A组(1.41±0.18)U/mL与(20.85±1.18)U/mL高(P<0.001)。结论双歧杆菌三联活菌胶囊联合四联疗法治疗Hp+CSG患者的效果显著,可提升Hp根除率,降低炎症反应、氧化应激水平,有利于改善预后。

CSG中医辨证分型与血浆MTL、GAS、SS水平关系的临床研究

目的为探讨慢性浅表性胃炎肝胃不和、脾胃虚弱、脾胃湿热三种中医证型与胃泌素、胃动素和生长抑素三种胃肠激素水平的关系。方法将CSG患者肝胃不和、脾胃虚弱、脾胃湿热三种中医证型各25例及健康成年人25例,用放射免疫分析法测定空腹血浆MTL、GAS、SS。结果CSG的三种中医辨证分型脾胃湿热、脾胃虚弱、肝胃不和的血浆MTL、GAS、SS水平,不仅与健康人有显著差异,且CSG的三种中医辨证分型与血浆MTL、GAS、SS存在着较密切的关系,并有一定的规律性。结论检测CSG患者的血浆MTL、GAS、SS水平,对提高CSG的中医辨证分型有积极意义,结果可作为中医临床参考。

基于网络药理学和分子对接探讨胃复春治疗慢性浅表性胃炎作用机制

目的:基于网络药理学探讨胃复春(WFC)治疗慢性浅表性胃炎(CSG)的分子机制。方法:采用中药系统药理学数据库与分析平台(TCMSP)、中药综合资源数据库(TCMID)及SwissTargetPrediction网站检索WFC的相关化学成分及其对应的作用靶点;利用GeneCard数据库、OMIM数据库筛选CSG的作用靶点,通过韦恩在线网站获取WFC与CSG的交集靶点,并通过Cytoscape 3.7.2软件构建蛋白互作网络图;根据拓扑学参数查找WFC治疗CSG的核心靶点,运用Cytoscape 3.7.2软件构建成分-核心靶点网络图筛选WFC作用于CSG的关键成分。利用David网站对交集靶点进行基因本体论(GO)和京都基因与基因组百科全书数据库(KEGG)通路富集分析,采用R软件绘制可视化气泡图。通过SYBYL-X2.1.1软件对WFC治疗CSG的主要活性成分及关键靶点进行分子对接。结果:WFC治疗CSG的关键成分为人参皂苷Rh2、柚皮素、14-乙酰基-耐阴午茶菜素b、β-谷甾醇等,关键靶点有白细胞介素-6(IL-6)、肿瘤坏死因子(TNF)、苏氨酸蛋白激酶1(AKT1)、血管内皮生长因子A(VEGFA)、抑癌基因53(TP53)等。WFC治疗CSG主要作用于癌症信号通路、脂质与动脉粥样硬化信号通路、卡波西肉瘤相关疱疹病毒感染等信号通路,其功能主要有参与RNA聚合酶Ⅱ启动子转录的正调控、信号转导及细胞凋亡过程的负调控,在蛋白质结合、ATP结合方面起重要作用等。分子对接结果显示,WFC中的关键成分14-乙酰基-耐阴午茶菜素b、人参皂苷Rh2、川陈皮素与关键靶点IL-6、AKT1、VEGFA的结合活性较强。结论:WFC可能通过调节IL-6、TNF、AKT1等靶点治疗CSG,其作用机制与癌症信号通路,脂质与动脉粥样硬化信号通路密切相关。

奥美拉唑联合阿莫西林治疗慢性浅表性胃炎的临床效果

目的观察奥美拉唑联合阿莫西林治疗慢性浅表性胃炎的效果。方法选取经胃镜诊断均为慢性浅表性胃炎的患者,均在福清市中医院于2021年8月至2023年1月期间收治,总计100例,采用随机数字表方法分组,对照组(50例,奥美拉唑治疗)和观察组(50例,奥美拉唑+阿莫西林治疗)。结果观察组慢性浅表性胃炎患者临床治疗总有效率高于对照组(P<0.05);观察组慢性浅表性胃炎患者纳差消失时间、恶心呕吐消失时间、腹胀消失时间均短于对照组(均P<0.05);治疗后,观察组慢性浅表性胃炎患者肿瘤坏死因子α、白细胞介素6、核转录因子水平、临床病理积分、疼痛评分均低于对照组(均P<0.05);治疗后,观察组慢性浅表性胃炎患者胃泌素水平低于对照组,胃动素水平高于对照组(均P<0.05);观察组慢性浅表性胃炎患者恶心、呕吐、头晕总不良反应发生率与对照组相近,对比结果差异不显著(P>0.05)。结论奥美拉唑联合阿莫西林治疗慢性浅表性胃炎的效果显著优于奥美拉唑。

基于数据挖掘探讨中医治疗脾胃湿热型慢性非萎缩性胃炎的用药规律

目的:探索分析中医药治疗脾胃湿热型慢性非萎缩性胃炎的用药规律。方法:收集中国知网数据库、万方数据库建库至2022年9月1日关于中医药治疗脾胃湿热证慢性非萎缩性胃炎的处方,筛选后导入中医传承计算平台V3.0,对录入处方中药物的使用频次、四气-五味、归经、功效进行分析,采用关联规则、k-means聚类算法进行演算进行分析。结果:共收集91首有效方剂,涉及中药112味。单味药用药频次以黄连最高,半夏次之;药性以寒性、温性为主,平性次之;药味以苦味、辛味最多,辅以甘味;归经中以脾经、胃经为主、肺经次之。功效主要为清热类药、补虚类药、化湿类药、理气类药。常用药物组合频次排前6位的分别为“黄连、半夏”“黄连、陈皮”“半夏、厚朴”“半夏、黄芩”“黄连、黄芩”“半夏、陈皮”;通过k-means聚类得到3对核心药物组合,分别为“黄连、半夏、陈皮、黄芩、厚朴”“厚朴、半夏、黄连、黄芩、甘草”“黄连、半夏、生姜、厚朴、苍术”。结论:中医药治疗脾胃湿热型慢性非萎缩性胃炎以清热燥湿、理气调中为治疗原则,以辛开苦降为重要指导思想,以恢复脾胃气机升降为主要目的,以半夏泻心汤及王氏连朴饮为治疗基础方。此方能通过降低机体炎症水平、抑制胃酸分泌、从而达到促进胃黏膜修复的作用,同时还能改善胃肠道动力,从而减轻患者临床症状,改善预后。

穴位贴敷联合艾灸治疗慢性浅表性胃炎疗效观察及对胃肠激素水平的影响

目的:观察穴位贴敷联合艾灸治疗慢性浅表性胃炎(CSG)的临床疗效以及对胃肠激素水平的影响。方法:选取100例CSG患者,按随机数字表法分为观察组和对照组各50例。对照组采用奥美拉唑肠溶胶囊联合艾灸治疗,观察组在对照组基础上加用穴位敷贴治疗。比较2组临床疗效、中医证候评分、胃肠激素[胃泌素(GAS)、生长抑素(SS)、胃动素(MLT)]水平以及不良反应。结果:观察组总有效率为86.00%,对照组为68.00%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组胃痛、饮食减少、恶心呕吐、善太息、嗳气吞酸等中医证候评分比较,差异均无统计学意义(P>0.05);治疗后,2组上述各项评分均较治疗前降低(P<0.05),且观察组各项评分均低于对照组(P<0.05)。治疗前,2组血清GAS、SS、MLT水平比较,差异无统计学意义(P>0.05)。治疗后,2组GAS水平均较治疗前降低(P<0.05),SS、MLT水平均较治疗前升高(P<0.05);且观察组GAS水平低于对照组(P<0.05),SS、MLT水平高于对照组(P<0.05)。治疗过程中,2组均未出现明显不良反应。结论:穴位贴敷联合艾灸治疗CSG疗效确切,可有效改善中医证候及胃肠激素水平,且治疗安全性良好。

温中健脾养胃汤治疗老年脾胃虚寒型慢性浅表性胃炎临床观察

目的 探究自拟温中健脾养胃汤治疗老年脾胃虚寒型慢性浅表性胃炎(CSG)的效果。方法 选取2018年3月—2021年3月蕲春县人民医院收治的脾胃虚寒型CSG患者100例,随机分为观察组(50例)、对照组(50例);对照组接受常规疗法,观察组在此基础上联合自拟温中健脾养胃汤。比较两组疗效,临床症状中医证候积分、幽门螺杆菌(Hp)转阴时间、胃黏膜病理学评分、白细胞计数(WBC)、白细胞介素-6(IL-6)以及肿瘤坏死因子-α(TNF-α)水平。结果 观察组治疗总有效率92.00%(46/50)显著高于对照组的74.00%(37/50)(P<0.05);观察组Hp转阴时间低于对照组(P<0.05),且中医证候积分、胃黏膜病理学评分、WBC计数、IL-6以及TNF-α水平亦低于对照组(P<0.05),差异有统计学意义。结论 温中健脾养胃汤辅助能提高CSG治疗总有效率、同时能缓解胃黏膜病理学和炎性反应。

耳穴压豆结合艾灸对脾胃虚弱型慢性浅表性胃炎患者生活质量及疼痛程度的影响分析

目的分析耳穴压豆结合艾灸对脾胃虚弱型慢性浅表性胃炎患者生活质量及疼痛程度的影响。方法选取60例脾胃虚弱型慢性浅表性胃炎患者,随机分为对照组和试验组,各30例。对照组患者采取常规方式治疗,试验组患者在对照组基础上采取耳穴压豆结合艾灸治疗。比较两组患者内镜下临床疗效及生活质量评分、疼痛评分。结果两组患者治疗前生活质量评分比较无差异(P>0.05);试验组患者治疗后生活质量评分(89.0±11.4)分高于对照组的(70.0±10.6)分,差异有统计学意义(P<0.05)。两组患者治疗前疼痛评分比较无差异(P>0.05);试验组患者治疗后疼痛评分(1.2±0.6)分低于对照组的(4.5±0.5)分,差异有统计学意义(P<0.05)。试验组患者内镜下总有效率93.33%高于对照组的56.67%,差异有统计学意义(P<0.05)。结论采取耳穴压豆结合艾灸治疗脾胃虚弱型慢性浅表性胃炎患者的效果显著,能改善患者的临床症状及生活质量,值得推广。

奥美拉唑联合阿莫西林治疗慢性浅表性胃炎的临床效果

本研究的目的是观察奥美拉唑联合阿莫西林治疗慢性浅表性胃炎的效果。选取经胃镜诊断均为慢性浅表性胃炎的患者,均在山东中医药大学附属医院于2022年1月至2023年7月期间收治,总计100例,采用随机对照的方法将患者分为两组,每组50例。对照组仅给予奥美拉唑治疗,而实验组则采用奥美拉唑联合阿莫西林治疗。两组患者的治疗持续时间均为4周。奥美拉唑的给药剂量为每天20mg,两次口服;阿莫西林的给药剂量为每天1000mg,口服两次。治疗期间,严格监测患者的临床症状、胃镜下病变的改善情况以及不良反应的发生。疗效评估标准包括临床症状缓解率、胃镜下病变愈合率和不良反应发生率。治疗结束后,两组患者的临床症状缓解率分别为80%和96%,显示实验组较对照组有更高的症状缓解率。胃镜下病变愈合率实验组为94%,对照组为78%,实验组的愈合率显著高于对照组(P<0.05)。在不良反应方面,两组的发生率相似,主要为轻至中度的消化系统症状,如恶心、腹泻等,且多在停药后自行缓解。此外,研究还对患者进行了幽门螺杆菌(HP)的检测,发现在实验组中,有较高比例的患者在治疗后HP检测转为阴性,而对照组中转阴率相对较低。这表明奥美拉唑联合阿莫西林治疗不仅能够改善慢性浅表性胃炎的临床症状和胃镜下病变,也可能有助于根除HP感染。由此可见,奥美拉唑联合阿莫西林治疗慢性浅表性胃炎在临床症状缓解、胃镜下病变愈合以及幽门螺杆菌根除方面均优于单独使用奥美拉唑治疗,且安全性良好,值得在临床上推广应用。

灵龟八法针灸辅助西药治疗慢性浅表性胃炎的疗效

目的 探究灵龟八法针灸辅助西药治疗慢性浅表性胃炎(CSG)的效果。方法 选取本院2022年1月~2023年1月收治的CSG患者100例,随机分为对照组、观察组,各50例。对照组接受西药治疗,观察组在对照的基础上接受灵龟八法针灸治疗。比较两组疗效、胃功能及淋巴细胞因子情况。结果 观察组总有效率96.00%,对照组82.00%(P<0.05);治疗后,观察组胃泌素-17(G-17)水平、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、PGⅠ/PGⅡ、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平低于对照组(P<0.05)。结论 采用灵龟八法针灸辅助西药治疗CSG疗效确切,可改善患者胃功能指标及淋巴细胞因子水平,减少炎性反应。

中西医结合治疗脾胃虚寒型慢性浅表性胃炎疗效及对外周血胃肠激素、T淋巴细胞亚群、IL-8、IL-32、MCP-1的影响

目的探讨加味黄芪建中汤联合艾司奥美拉唑治疗脾胃虚寒型慢性浅表性胃炎(chronic superficial gastritis,GAS)的效果。方法选择2019年10月—2021年5月收治的190例脾胃虚寒型慢性浅表性胃炎患者进行研究,使用随机数字表将其分为试验组和对照组,每组95例,对照组接受艾司奥美拉唑治疗,试验组接受加味黄芪建中汤联合艾司奥美拉唑治疗,共治疗8周,比较两组外周血胃肠激素、T淋巴细胞亚群、白细胞介素(interleukin,IL)-8、IL-32、单核细胞趋化因子-1(monocyte chemotactic protein 1,MCP-1)水平,比较两组治疗前后中医证候积分以及中医证候疗效。结果治疗后试验组胃动力素(motilin,MTL)、CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)水平均高于对照组,差异具有统计学意义(P<0.05),试验组慢性浅表性胃炎、P物质(SP)、CD_(8)^(+)、IL-8、IL-32、MCP-1以及中医证候积分均低于对照组,差异具有统计学意义(P<0.05),试验组中医证候疗效优于对照组,差异具有统计学意义(P<0.05)。结论加味黄芪建中汤联合艾司奥美拉唑治疗脾胃虚寒型慢性浅表性胃炎具有确切的疗效,可有效调节胃肠激素的分泌,改善免疫功能,抑制炎症反应,适合在临床推广应用。

柴龙逆萎汤辅助治疗肝胃不和证慢性浅表性胃炎的效果分析

目的分析柴龙逆萎汤辅助治疗肝胃不和证慢性浅表性胃炎的临床疗效。方法回顾性分析2020年7月至2021年6月南京市中医院收治的84例慢性浅表性胃炎患者(肝胃不和证),根据治疗方法不同分为A组(n=42)与B组(n=42)。B组使用多潘立酮片治疗,A组使用多潘立酮片联合自拟柴龙逆萎汤治疗,比较两组中医证候评分、胃肠激素水平、炎症指标水平及不良反应情况。结果治疗后,两组中医证候评分、白介素(IL)-32、人表皮生长因子(EGF)明显降低,且A组低于B组,差异有统计学意义(P<0.05);胃动素、胃泌素、降钙素基因相关肽(CGRP)水平明显升高,且A组高于B组,差异有统计学意义(P<0.05);A组不良反应总发生率明显低于B组,差异有统计学意义(P<0.05)。结论采用柴龙逆萎汤辅助治疗肝胃不和证慢性浅表性胃炎可有效改善临床症状,提高胃肠激素水平,缓解胃黏膜损伤及炎症反应,具有较高治疗安全性。

健脾和胃汤辅治慢性浅表性胃炎多并症的临床效果

目的观察慢性浅表性胃炎多并症患者采取健脾和胃汤治疗的临床效果。方法选取2017年9月—2020年8月福建中医药大学附属三明中西医结合医院/三明市中西医结合医院收治的慢性浅表性胃炎多并症患者80例,根据随机数字表法分为中药联合组和常规用药组,每组40例。中药联合组在常规抗感染治疗基础上联合健脾和胃汤治疗,常规用药组在常规抗感染治疗基础上予多潘立酮片、雷贝拉唑治疗,2组患者均治疗2周。比较2组治疗效果、临床症状改善时间、住院时间,治疗前后炎性指标、急性生理与慢性健康评分(APACHE-Ⅱ)变化及不良反应。结果中药联合组治疗总有效率为97.50%,高于常规用药组的77.50%(χ^(2)=7.314,P=0.007);中药联合组胃部疼痛改善时间、食欲减退恢复时间与住院时间均短于常规用药组(P<0.01);治疗2周后,2组白介素-6(IL-6)、C反应蛋白(CRP)、降钙素原(PCT)、D-二聚体(D-D)水平较治疗前均降低,且中药联合组低于常规用药组(P均<0.01);2组APACHE-Ⅱ评分较治疗前均下降,且中药联合组低于常规用药组(P均<0.01);中药联合组不良反应总发生率为2.50%,低于常规用药组的25.00%(χ^(2)=8.538,P=0.003)。结论慢性浅表性胃炎多并症患者在常规抗感染治疗基础上联合健脾和胃汤治疗效果佳,有助于改善病情,缩短胃部疼痛改善时间,降低患者不适感,减少不良反应,安全性高,可临床推广应用。

金胃泰胶囊联合三联疗法治疗慢性浅表性胃炎临床研究

目的:观察金胃泰胶囊联合三联疗法治疗慢性浅表性胃炎的临床疗效。方法:选取135例慢性浅表性胃炎患者,按随机数字表法分为治疗组68例与对照组67例。对照组给予三联疗法治疗,治疗组在对照组的基础上联合金胃泰胶囊治疗。治疗1个月后观察2组临床疗效及复发率,以及治疗前后中医证候评分、血清胃动素(MTL)、胃泌素(GAS)水平。结果:治疗组总有效率为95.59%,对照组为83.58%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组胃脘胀满、胁肋疼痛、恶心、嗳气、大便不爽等中医证候评分均较治疗前降低(P<0.05),且治疗组各项中医证候评分均低于对照组(P<0.05)。治疗前,2组血清MTL、GAS水平比较,差异无统计学意义(P>0.05);治疗后,2组MTL、GAS水平均较治疗前升高(P<0.05),且治疗组MTL、GAS水平高于对照组(P<0.05)。治疗组复发率为7.69%,对照组为21.43%,2组比较,差异有统计学意义(P<0.05)。结论:金胃泰胶囊联合三联疗法治疗慢性浅表性胃炎疗效肯定,可显著缓解中医证候,有效调节胃肠激素水平,降低疾病复发率。